Neuro, sleep & melanocortin
Beyond metabolism and growth sit a set of peptides studied for the nervous system: melanocortin agonists like PT-141, nootropic peptides like Semax, and sleep neuropeptides like DSIP.
These three compounds do not share a single receptor the way the metabolic or growth families do, they are grouped because each is studied for a central or neurological pathway. All three are currently marked Coming soon in the catalogue.
Melanocortin agonists
PT-141, also known as Bremelanotide (~1025.2 Da), acts on melanocortin receptors in the central nervous system. The key point for research framing is that it works through a central pathway rather than through the vascular system, a different mechanism from compounds that act on blood vessels directly. It is part of the broader melanocortin family of signalling peptides.
Central, not vascular
PT-141's activity is studied at CNS melanocortin receptors, a central pathway. That distinction defines how it is researched.
Nootropic peptides
Semax (~813.9 Da) is a synthetic heptapeptide based on the ACTH 4-10 fragment. In research it is investigated for nootropic and neuroprotective effects, with particular interest in the upregulation of BDNF (brain-derived neurotrophic factor) in study models.
Semax
Synthetic heptapeptide based on ACTH 4-10. Researched for nootropic and neuroprotective effects.
BDNF interest
Study models look at upregulation of brain-derived neurotrophic factor.
Sleep & neuropeptides
DSIP, Delta Sleep-Inducing Peptide (~848.9 Da), is a neuropeptide investigated for its role in sleep regulation, stress response and circadian-rhythm modulation. Research models examine how it interacts with the body's natural sleep and stress signalling.